Description

Based in Leverkusen, Germany, Biofrontera AG is a biopharmaceutical firm established in 1997, dedicated to the innovation, development, and marketing of skincare therapies. Its primary offerings include Ameluz, paired with the BF-RhodoLED lamp, engineered to address mild to moderate actinic keratoses on the face and scalp, field cancerization, and aggressive squamous cell carcinoma. The company also provides RhodoLED XL for managing multiple dispersed lesions, Belixos, an advanced cosmetic line for sensitive and irritated skin, and Xepi, a solution targeting antibiotic-resistant bacterial infections. Biofrontera's products are distributed mainly across the United States, Europe, and Israel, and its operations are strengthened by a collaboration agreement with Maruho Co., Ltd.